GLOBAL HYPERPHOSPHATEMIA DRUG MARKET FORECAST 2019-2027

  • You are here:
  • Home
  • Reports
  • GLOBAL HYPERPHOSPHATEMIA DRUG MARKET FORECAST 2019-2027

GLOBAL HYPERPHOSPHATEMIA DRUG MARKET FORECAST 2019-2027

The Global hyperphosphatemia drugs market is anticipated to grow at a CAGR of 16.13% between 2019 and 2027. The hyperphosphatemia drug market has been bifurcated based on the formulation that includes several types of phosphate binders such as Calcium-based phosphate binders, Aluminum based phosphate binders, and Magnesium based phosphate binders, and Iron-based phosphate binders and others. The following factors primarily drive the Hyperphosphatemia drugs market:

GLOBAL HYPERPHOSPHATEMIA DRUG MARKET FORECAST 2019-2027

Global Hyperphosphatemia Drugs Market by Formulation (Calcium-based Phosphate Binders, Aluminum-based Phosphate Binders, Magnesium-based Phosphate Binders, Iron-based Phosphate Binders) & by Geography.

Request free sample

The Global hyperphosphatemia drugs market is anticipated to grow at a CAGR of 16.13% between 2019 and 2027. The hyperphosphatemia drug market has been bifurcated based on the formulation that includes several types of phosphate binders such as Calcium-based phosphate binders, Aluminum based phosphate binders, and Magnesium based phosphate binders, and Iron-based phosphate binders and others. The following factors primarily drive the Hyperphosphatemia drugs market:

  • Growing prevalence of chronic diseases
  • Unmet medical needs
  • Skewed population mix towards elderly people
  • Rise in public awareness

Global HYPERPHOSPHATEMIA DRUG MARKET   To learn more about this report, request a free sample copy

The important driver increasing growth in the worldwide hyperphosphatemia drugs arcade is growing prevalence of chronic diseases. The International Diabetes Federation reported in 2015 than 387 million people had diabetes in the same year, which is expected to increase to 592 million by 2035.

The Formulation of Hyperphosphatemia drugs market is used extensively for various purposes. Calcium-based phosphate binders replaced aluminum-based phosphate binders and are using since the 1990s. They are also used as calcium supplements. Aluminium-containing phosphate binders have long been used for the treatment of hyperphosphatemia in dialysis patients. The magnesium-based phosphorus binders are widely used phosphorus binders that have remarkably being engaged in the curing of hyperphosphatemia conditions all through the dialysis patients. Iron-based phosphate binders like sevelamer are effective in treating hyperphosphatemia and anemia. These binders are associated with iron overload in the body. The other phosphorus binders are extensively used forms to cure severe hyperphosphatemia conditions in the dialysis patients.

Limitations Levied by the Food and Drug Administration (FDA) And Growing Side Effects of the Hyperphosphatemia Drugs are the major factors hindering the Hyperphosphatemia drugs market. According to the Food and Drug Administration (FDA), use of hyperphosphatemia drug for the treatment of high or low plasma level of phosphorous in the human body is not recognized as safe and effective. Another factor restraining the hyperphosphatemia drugs market is the growing side effects of hyperphosphatemia drugs. The only alternative way to prevent and treat hyperphosphatemia is to keep phosphate consumption balanced in the daily diet.

The Global Hyperphosphatemia drugs market segments include Formulation.

The formulation is segmented into:

  • Aluminum-based phosphate binders
  • Iron-based phosphate binders
  • Calcium-based phosphate binders
  • Magnesium-based phosphate binders
  • Other phosphate binders

This report covered the present market conditions and the growth prospects of the global Hyperphosphatemia drugs market for 2019-2027 and considered the revenue generated through the sales of Hyperphosphatemia drugs for the formulation to calculate the market size by considering 2017 as the base year.

Geographically, the global Hyperphosphatemia drugs market has been segmented on the basis of four major regions, which include:

The Hyperphosphatemia drugs market in North America is expected to hold the largest share by 2027 possibilities of the rising aging population, increasing cases of osteoporosis and the changing dietary habits. Among these, increasing osteoporosis disease is the major significant driving factor for the hyperphosphatemia drugs market in North America. It is estimated that around 61 million men and women in this same age category will be affected by osteoporosis by 2020, which is quite high as compared to the 2010 scenario when nearly 52 million people were affected in the USA.

On the other hand, the Asia-Pacific market is anticipated to the fastest-growing region for the Hyperphosphatemia drugs market. The growth of the Asia-Pacific market is primarily driven due to the rising aging population, increasing osteoporosis cases and changing dietary habits. Among these, increasing osteoporosis disease is the major significant driving factor for the hyperphosphatemia drugs market in the Asia-Pacific.

The major market players in the global Hyperphosphatemia drugs market are:

  • SANOFI
  • JOHNSON AND JOHNSON
  • AMAG PHARMACEUTICALS
  • FRESENIUS MEDICAL CARE
  • SHIRE

Company Profiles covers analysis of important players.

Shire Plc. (the Shire or ‘the company’) is engaged in the development and marketing of innovative medicines for patients with rare diseases and other special conditions. The company primarily operates in North America and Europe. Sanofi SA (Sanofi or ‘the group’) is a global healthcare company engaged in the research, development, manufacture, and marketing of therapeutic solutions. The group operates in about 100 countries across the world encompassing North America, Europe, and other countries.

Key Findings of the Global Hyperphosphatemia drugs market:

  • China is the largest healthcare drugs and equipment market in the Asia-pacific region
  • Iron-based hyperphosphatemia drugs is a game changer
  1. RESEARCH SCOPE
    • STUDY GOALS
    • SCOPE OF THE MARKET STUDY
    • WHO WILL FIND THIS REPORT USEFUL?
    • STUDY AND FORECASTING YEARS
  2. RESEARCH METHODOLOGY
    • SOURCES OF DATA
      • SECONDARY DATA
      • PRIMARY DATA
    • TOP DOWN APPROACH
    • BOTTOM-UP APPROACH
    • DATA TRIANGULATION
    • ESTIMATION METHODOLOGY
  3. EXECUTIVE SUMMARY
    • MARKET SUMMARY
    • KEY FINDINGS
      • CHINA IS THE LARGEST HEALTHCARE DRUGS AND EQUIPMENT MARKET IN ASIA-PACIFIC REGION
      • IRON-BASED HYPERPHOSPHATEMIA DRUGS IS A GAME CHANGER
  1. MARKET DETERMINANTS
    • MARKET SCOPE & DEFINITION
    • DRIVERS
      • GROWING PREVALENCE OF CHRONIC DISEASES
      • UNMET MEDICAL NEEDS
      • SKEWED POPULATION MIX TOWARDS ELDERLY PEOPLE
      • RISE IN PUBLIC AWARENESS
    • RESTRAINTS
      • LIMITATIONS LEVIED BY THE FOOD AND DRUG ADMINISTRATION (FDA)
      • GROWING SIDE EFFECTS OF THE HYPERPHOSPHATEMIA DRUGS
    • OPPORTUNITIES
      • ASIA PACIFIC REGIONS ARE EXPECTED TO PROPEL THE MARKET GROWTH
    • CHALLENGES
      • NON-ADHERENCE TO TREATMENT REGIMENS
      • SIDE EFFECTS OF DRUGS
      • LIMITED AVAILABILITY OF DRUGS
      • USE OF ADVANCED DIALYSIS TECHNIQUES
    • MARKET BY DOSAGE
      • SOLID
        • TABLET
        • POWDER
      • LIQUID
        • SOLUTION
  1. MARKET BY FORMULATION
    • CALCIUM-BASED PHOSPHATE BINDERS
    • ALUMINUM-BASED PHOSPHATE BINDERS
    • MAGNESIUM-BASED PHOSPHATE BINDERS
    • IRON-BASED PHOSPHATE BINDERS
    • OTHER PHOSPHATE BINDERS
  2. KEY ANALYTICS
    • PORTER’S FIVE FORCE MODEL
      • THREAT OF NEW ENTRANTS
      • BARGAINING POWER OF BUYERS
      • BARGAINING POWER OF SUPPLIERS
      • THREAT OF SUBSTITUTE PRODUCT
      • INTENSITY OF COMPETITIVE RIVALRY
    • OPPORTUNITY MATRIX
    • KEY BUYING CRITERIA
      • APPLICATION
      • PRICING
      • EFFECTIVENESS
      • AVAILABILITY
    • STRATEGIC RECOMMENDATION & STRATEGIC CONCLUSIONS
    • MARKET TRENDS
      • PATIENT ASSISTANCE PROGRAMS
      • STRATEGIC ALLIANCES
      • INCREASE IN R&D
    • PHOSPHATE BINDERS USAGES GUIDELINES
  3. GEOGRAPHIC ANALYSIS
    • NORTH AMERICA
      • THE UNITED STATES
      • CANADA
    • EUROPE
      • THE UNITED KINGDOM
      • FRANCE
      • GERMANY
      • SPAIN
      • ITALY
      • REST OF EUROPE (ROE)
    • ASIA PACIFIC
      • INDIA
      • CHINA
      • JAPAN
      • AUSTRALIA
      • SOUTH KOREA
      • REST OF APAC
    • REST OF THE WORLD
      • LATIN AMERICA
      • MIDDLE EAST AND AMERICA
  1. COMPETITIVE LANDSCAPE
    • MARKET SHARE ANALYSIS
    • COMPANY PROFILES
      • AMAG PHARMACEUTICALS
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • BIOTECH PHARMACAL
        • OVERVIEW
        • PRODUCTS PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • BRUNO FARMACEUTICI SPA
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • CIPLA
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • FERMENTA BIOTECH LTD
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • FRESENIUS MEDICAL CARE
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • JOHNSON AND JOHNSON
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • KERYX BIOPHARMACEUTICALS INC
        • OVERVIEW
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • PFIZER INC.
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • ROCHE DIAGNOSTICS CORPORATION
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • ROYAL DSM N.V.
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • SANOFI
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • SHIRE
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • SUN PHARMACEUTICAL INDUSTRIES LTD
        • OVERVIEW
        • PRODUCTS PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • ULTRAGENYX PHARMACEUTICAL INC.
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • ZERIA PHARMACEUTICAL
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES

 

LIST OF TABLES

TABLE  1      GLOBAL HYPERPHOSPHATEMIA DRUG MARKET BY REGION 2019-2027($ MILLION)

TABLE  2      IRON-BASED HYPERPHOSPHATEMIA DRUG APPROVAL STATUS  2014-2017

TABLE  3      GLOBAL PREVALENCE OF DIABETES 2015 AND 2035 (MILLIONS)

TABLE  4      WORLDWIDE POPULATION AGED 80 AND ABOVE 1950-2050 (MILLIONS)

TABLE  5      PHOSPHOROUS LEVELS IN SELECT FOODS

TABLE  6      GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET BY FORMULATION 2019-2027($ MILLION)

TABLE  7      GLOBAL CALCIUM-BASED PHOSPHATE BINDERS  BY REGION 2019-2027($ MILLION)

TABLE  8      GLOBAL ALUMINUM-BASED PHOSPHATE BINDERS  BY REGION 2019-2027($ MILLION)

TABLE  9      GLOBAL MAGNESIUM-BASED PHOSPHATE BINDERS BY REGION 2019-2027($ MILLION)

TABLE  10    GLOBAL IRON-BASED PHOSPHATE BINDERS  BY REGION 2019-2027($ MILLION)

TABLE  11    GLOBAL OTHER PHOSPHATE BINDERS BY REGION 2019-2027($ MILLION)

TABLE  12    PIPELINE PORTFOLIO OF HYPERPHOSPHATEMIA DRUGS

TABLE  13    GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET BY REGION 2019-2027 ($ MILLION)

TABLE  14    NORTH AMERICA HYPERPHOSPHATEMIA DRUGS MARKET BY COUNTRY 2019-2027($ MILLION)

TABLE  15    EUROPE HYPERPHOSPHATEMIA DRUGS MARKET BY COUNTRY 2019-2027($ MILLION)

TABLE  16    ASIA-PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET BY COUNTRY 2019-2027($ MILLION)

TABLE  17    PER CAPITA CONSUMPTION OF DAIRY PRODUCTS IN AUSTRALIA 2014 -2016

TABLE  18    REST OF THE WORLD HYPERPHOSPHATEMIA DRUGS MARKET BY COUNTRY 2019-2027($ MILLION)

LIST OF FIGURES

FIGURE  1    RATE OF ADHERENCE TO PHOSPHATE BINDERS

FIGURE  2    DIAGNOSIS AND CLINICAL INDICATORS OF CHRONIC KIDNEY DISEASE

FIGURE  3    GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET BY CALCIUM-BASED PHOSPHATE BINDERS 2019-2027($ MILLION)

FIGURE  4    GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET BY ALUMINUM-BASED PHOSPHATE BINDERS 2019-2027($ MILLION)

FIGURE  5    GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET BY MAGNESIUM-BASED PHOSPHATE BINDERS 2019-2027($ MILLION)

FIGURE  6    GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET BY IRON-BASED PHOSPHATE BINDERS 2019-2027($ MILLION)

FIGURE  7    GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET BY OTHER PHOSPHATE BINDERS 2019-2027($ MILLION)

FIGURE  8    PORTERS 5 FORCE MODEL OF HYPERPHOSPHATEMIA MARKET

FIGURE  9    INVESTMENT PREPOSITION ACROSS REGIONS 2019-2027

FIGURE  10  GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET SHARE, BY REGION 2019 & 2027 (%)

FIGURE  11  NORTH AMERICA HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027($ MILLION)

FIGURE  12  THE UNITED STATES HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027($ MILLION)

FIGURE  13  CANADA HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027($ MILLION)

FIGURE  14  EUROPE HYPERPHOSPHATEMIA DRUGS MARKET  2019-2027($ MILLION)

FIGURE  15  THE UNITED KINGDOM HYPERPHOSPHATEMIA DRUGS MARKET  2019-2027($ MILLION)

FIGURE  16  FRANCE HYPERPHOSPHATEMIA DRUGS MARKET  2019-2027($ MILLION)

FIGURE  17  GERMANY HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027($ MILLION)

FIGURE  18  SPAIN HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027($ MILLION)

FIGURE  19  ITALY HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027($ MILLION)

FIGURE  20  REST OF EUROPE  HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027($ MILLION)

FIGURE  21  ASIA-PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027($ MILLION)

FIGURE  22  AGE WISE DISTRIBUTION OF ELDERLY POPULATION IN INDIA 2016

FIGURE  23  INDIA HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027($ MILLION)

FIGURE  24  CHINA HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027($ MILLION)

FIGURE  25  JAPAN  HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027($ MILLION)

FIGURE  26  NUMBER OF FRACTURES DUE TO OSTEOPOROSIS AND OSTEOPENIA ($ MILLION)

FIGURE  27  AUSTRALIA HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027($ MILLION)

FIGURE  28  SOUTH KOREA HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027($ MILLION)

FIGURE  29  ROAPAC HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027($ MILLION)

FIGURE  30  REST OF THE WORLD  HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027($ MILLION)

FIGURE  31  LATIN AMERICA HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027($ MILLION)

FIGURE  32  MENA HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027($ MILLION)

FIGURE  33  MARKET SHARE ANALYSIS OF KEY PLAYERS 2017 (%)

  1. MARKET SEGMENTATION
    • MARKET BY FORMULATION 2019-2027
      • CALCIUM-BASED PHOSPHATE BINDERS
      • ALUMINIUM-BASED PHOSPHATE BINDERS
      • MAGNESIUM-BASED PHOSPHATE BINDERS
      • IRON-BASED PHOSPHATE BINDERS
      • OTHER PHOSPHATE BINDERS
  1. GEOGRAPHIC ANALYSIS
    • NORTH AMERICA
      • UNITED STATES
      • CANADA
    • EUROPE
      • UNITED KINGDOM
      • FRANCE
      • GERMANY
      • SPAIN
      • ITALY
      • REST OF EUROPE (ROE)
    • ASIA PACIFIC
      • INDIA
      • CHINA
      • JAPAN
      • AUSTRALIA
      • REST OF APAC
    • REST OF THE WORLD
      • LATIN AMERICA
      • MIDDLE EAST AND NORTH AMERICA (MENA)
      • REST OF AFRICA

To request a free sample copy of this report, please complete the form below :
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

Choose License Type

Buy Now